Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-08-10 21:31:51 ET · period of report 2026-08-07 · accession 0001636282-26-000102 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | M - OptEx | $10.39 | +5,000 | 5,000 | New | +$52.0K |
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | S - Sale+OE | $104.47 | -5,000 | 0 | -100% | -$522.4K |
| DMTI | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | S - Sale+OE | $104.55 | -18.0K | 9,360 | -66% | -$1.88M |
| DT | 2026-08-10 21:31 | 2026-08-07 | SYRE | Albers Jeffrey W. | Dir | M - OptEx | $0.00 | -5,000 | 45.0K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-07 | M | A | 5,000 | $10.39 | 5,000 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. |
| 2 | Common | Common Stock | 2026-08-07 | S | D | 5,000 | $104.47 | 0 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2026-08-07 | S | D | 8,000 | $104.38 | 19,360 | I By Sessions LLC | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F3) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2026-08-07 | S | D | 10,000 | $104.68 | 9,360 | I By Sessions LLC | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F4) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-08-07 | M | D | 5,000 | $0.00 | 45,000 | D | $10.39 · — to 2033-11-22 | 5,000 Common Stock | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F5) This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |